"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D001384
|
| MeSH Number(s) |
D03.383.082.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 4 | 1 | 5 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 2 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i18-i23.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 09 16; 135(18).
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
-
Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
-
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
-
Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury. Cell Mol Gastroenterol Hepatol. 2019; 8(3):379-405.
-
Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream? Ann Rheum Dis. 2019 02; 78(2):153-154.
-
Targeted Apoptosis of Parietal Cells Is Insufficient to Induce Metaplasia in Stomach. Gastroenterology. 2017 03; 152(4):762-766.e7.